Nyotran lipid formulation of nystatin data

ARNX reported interim results from Phase II/III testing in 57 patients with candidemia. The patients, with normal

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE